Vishnu Vardhan Garla1,2,3, Javed Butler4, Lillian F Lien5. 1. Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA. vgarla@umc.edu. 2. Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS, USA. vgarla@umc.edu. 3. , Jackson, USA. vgarla@umc.edu. 4. Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA. 5. Endocrinology, Metabolism and Diabetes, Dept. of Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Abstract
PURPOSE OF REVIEW: Heart failure is responsible for a significant part of diabetes-associated cardiovascular mortality and morbidity. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are novel agents approved for the treatment of diabetes mellitus; in recent clinical trials, these agents have shown a significant reduction in cardiovascular death and hospitalization secondary to heart failure. RECENT FINDINGS: Clinical trials with specific heart failure outcomes have shown the benefit of SGLT-2 inhibitors in reducing the mortality and morbidity associated with heart failure. The guidelines for the management of diabetes mellitus recommend the preferential use of SGLT-2 inhibitors in patients with a history of cardiovascular disease. SGLT-2 inhibitors are potential game changers in the treatment of heart failure. Guidelines for prescription of these agents help assess risk-benefit analysis and personalize treatment for maximal benefit.
PURPOSE OF REVIEW: Heart failure is responsible for a significant part of diabetes-associated cardiovascular mortality and morbidity. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are novel agents approved for the treatment of diabetes mellitus; in recent clinical trials, these agents have shown a significant reduction in cardiovascular death and hospitalization secondary to heart failure. RECENT FINDINGS: Clinical trials with specific heart failure outcomes have shown the benefit of SGLT-2 inhibitors in reducing the mortality and morbidity associated with heart failure. The guidelines for the management of diabetes mellitus recommend the preferential use of SGLT-2 inhibitors in patients with a history of cardiovascular disease. SGLT-2 inhibitors are potential game changers in the treatment of heart failure. Guidelines for prescription of these agents help assess risk-benefit analysis and personalize treatment for maximal benefit.
Entities:
Keywords:
Euglycemic diabetic ketoacidosis; Heart failure; Hospitalization for heart failure; Major adverse cardiovascular events; Sodium-glucose cotransporter-2 inhibitors
Authors: David C Klonoff; Nicole Y Xu; Kevin T Nguyen; David Kerr; Chhavi Mehta; Guillermo E Umpierrez; George A Brooks Journal: J Diabetes Sci Technol Date: 2022-06-02